Sinclair
- Consolidated Income Statement
- Balance Sheet
- Statement of Changes in Shareholders' Equity
- Cash Flow Statements
- Notes to the Financial Statements
- 1. General information
- 2. Accounting Policies
- 3. Financial risk management
- 4. Segmental information
- 5. Exceptional operating items
- 6. Expenses by nature
- 7. Employees and Directors
- 8. Finance Income and costs
- 9. Taxation on loss on ordinary activities
- 10. Loss for the financial year
- 11. Loss per share
- 12. Goodwill
- 13. Intangible asssets
- 14. Property, plant and equipment
- 15. Investments
- 16. Deferred tax asset
- 17. Inventories
- 18. Trade and other receivables
- 19. Trade and other payables
- 20. Borrowings
- 21. Provisions
- 22. Financial instruments
- 23. Called-up share capital
- 24. Share premium
- 25. Options and warrants over shares of Sinclair Pharma plc
- 26. Share based payments
- 27. Other Reserves
- 28. Cash flows from operating activities
- 29. Operating lease commitments
- 30. Capital commitments
- 31. Related party transactions
- 32. Post balance sheet events
|
Notes to the Financial Statementsfor the year ended 30 June 2009 1 General informationThe Company is a public limited company which is listed on the London Stock Exchange, and Euronext, Paris and is incorporated and domiciled in the United Kingdom. The address of its registered office is Unit 4, Godalming Business Centre, Woolsack Way, Godalming, Surrey, GU7 1XW.
|